BACKGROUND: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity conditioning (RIC) and followed by allogeneic SCT has not been investigated to date. METHODS: PET was used to assess 80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they underwent allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients underwent allograft from matched related siblings (n=41) or alternative donors (n=39). RESULTS: At the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was significantly lower in the PET-negative patients (25% vs 56%; P=.007), but there was no significant difference between the patients with or without chronic graft-versus-host disease (P=.400). The patients who had negative PET studies before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs 33%; P=.001) and 3-year progression-free survival (73% vs 31%; P=.001). On multivariate analysis, overall survival was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26 for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling). CONCLUSIONS: The current results indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for RIC allografting.
BACKGROUND: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity conditioning (RIC) and followed by allogeneic SCT has not been investigated to date. METHODS: PET was used to assess 80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they underwent allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients underwent allograft from matched related siblings (n=41) or alternative donors (n=39). RESULTS: At the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was significantly lower in the PET-negative patients (25% vs 56%; P=.007), but there was no significant difference between the patients with or without chronic graft-versus-host disease (P=.400). The patients who had negative PET studies before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs 33%; P=.001) and 3-year progression-free survival (73% vs 31%; P=.001). On multivariate analysis, overall survival was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26 for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling). CONCLUSIONS: The current results indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for RIC allografting.
Authors: V Bachanova; Q Cao; C Ustun; A T K Kendi; J Froelich; A Lazaryan; L J Burns Journal: Bone Marrow Transplant Date: 2014-09-29 Impact factor: 5.483
Authors: L Castagna; R Crocchiolo; L Giordano; S Bramanti; C Carlo-Stella; B Sarina; A Chiti; E Mauro; S Gandolfi; E Todisco; M Balzarotti; A Anastasia; M Magagnoli; E Brusamolino; A Santoro Journal: Bone Marrow Transplant Date: 2015-01-26 Impact factor: 5.483
Authors: Erik Magnusson; Qing Cao; Michael A Linden; Jerry Frolich; Vidhu Anand; Linda J Burns; Veronika Bachanova Journal: Clin Lymphoma Myeloma Leuk Date: 2013-11-15
Authors: Veronika Bachanova; Linda J Burns; Kwang Woo Ahn; Ginna G Laport; Görgün Akpek; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Edward Agura; Philippe Armand; Samantha M Jaglowski; Mitchell S Cairo; Amanda F Cashen; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Nilanjan Ghosh; Leona A Holmberg; David J Inwards; Abraham S Kanate; Hillard M Lazarus; Adriana K Malone; Reinhold Munker; Alberto Mussetti; Maxim Norkin; Tim D Prestidge; Jacob M Rowe; Prakash Satwani; Tanya Siddiqi; Patrick J Stiff; Basem M William; Baldeep Wirk; David G Maloney; Sonali M Smith; Anna M Sureda; Jeanette Carreras; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2015-05-14 Impact factor: 5.742
Authors: Alison J Moskowitz; Paul A Hamlin; Miguel-Angel Perales; John Gerecitano; Steven M Horwitz; Matthew J Matasar; Ariela Noy; Maria Lia Palomba; Carol S Portlock; David J Straus; Tricia Graustein; Andrew D Zelenetz; Craig H Moskowitz Journal: J Clin Oncol Date: 2012-12-17 Impact factor: 44.544
Authors: Craig S Sauter; Lauren Lechner; Michael Scordo; Junting Zheng; Sean M Devlin; Stephen E Fleming; Hugo Castro-Malaspina; Craig H Moskowitz Journal: Biol Blood Marrow Transplant Date: 2014-02-15 Impact factor: 5.742